Semaglutide, a glucagon-like peptide receptor agonist (GLP- 1 RA), was shown in STEP 1 to produce mean weight reduction from baseline to week 68 of 14.9% for semaglutide versus 2.4% for placebo, by treatment-policy or treatment-regimen estimand which is reported throughout this manuscript, except where noted [1]
If you are a female reproductive potential: Zepbound may reduce the efficacy of oral hormonal contraceptives
Weakness or feeling lightheaded
it is metabolically active and can release inflammatory molecules known as adipokines
The EMAs Pharmacovigilance Risk Assessment Committee (PRAC) that monitors side effects of pharmaceuticals, will examine a "signal of aspiration and pneumonia aspiration" associated with GLP-1 receptor agonists (GLP-1 ra)
Important considerations for muscle health: Rapid weight loss may affect muscle mass Gastrointestinal side effects may contribute to perceived muscle pain Proper protein intake is essential during treatment [2] Regular exercise helps maintain muscle strength Recent findings indicate that some GLP-1 receptor agonists have been associated with muscle mass loss, which could potentially lead to sarcopenia and bone density issues
)
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
